The Burden of Progressive Fibrosing Interstitial Lung Disease: A DELPHI Approach

被引：0
作者：
Wim A. Wuyts
Spyridon Papiris
Effrosyni Manali
Maritta Kilpeläinen
Jesper Rømhild Davidsen
Jelle Miedema
Carlos Robalo-Cordeiro
Antonio Morais
Maite Artés
Guus Asijee
David Cendoya
Stéphane Soulard
机构：
[1] University Hospitals Leuven,Unit for Interstitial Lung Diseases, Department of Respiratory Medicine
[2] National and Kapodistrian University of Athens,2nd Pulmonary Medicine Department, General University Hospital “Attikon”, Medical School
[3] Turku University Hospital and University of Turku,Division of Medicine, Department of Pulmonary Diseases and Clinical Allergology
[4] Odense University Hospital,South Danish Center for Interstitial Lung Diseases, Department of Respiratory Medicine
[5] Erasmus University Medical Centre,Department of Respiratory Medicine
[6] University Hospital of Coimbra,Department of Pulmonology and Allergy
[7] Diffuse Lung Diseases Unit,Department of Pneumology of São João Hospital Centre
[8] Adelphi Spain,undefined
[9] Boehringer Ingelheim,undefined
来源：
Advances in Therapy | 2020年 / 37卷
关键词：
Burden of disease; Consensus; Cost study; Delphi; European countries; Interstitial lung disease; Progressive fibrosing; Pulmonary; Societal impact;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：3246 / 3264
页数：18
相关论文
共 98 条
[1]  
Cottin V(2018)Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases Eur Respir Rev 27 180076-824
[2]  
Hirani NA(2011)An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management Am J Respir Crit Care Med 183 788-7
[3]  
Hotchkin DL(2017)Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease BMJ Open Respir Res 4 1-12
[4]  
Nambiar AM(2018)What’s in a name? That which we call IPF, by any other name would act the same Eur Respir J 51 1-1129
[5]  
Ogura T(2018)The epidemiology of idiopathic pulmonary fibrosis and interstitial lung diseases at risk of a progressive-fibrosing phenotype Eur Respir Rev 27 180077-118s
[6]  
Otaola M(2017)Prevalence and incidence of interstitial lung diseases in a multi-ethnic county of Greater Paris Eur Respir J 50 1602419-807
[7]  
Raghu G(2009)Epidemiology of interstitial lung diseases in Greece Respir Med 103 1122-1727
[8]  
Collard HR(2001)Comparison of registries of interstitial lung diseases in three European countries Eur Respir J Suppl 32 114s-363
[9]  
Egan JJ(2017)Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: insights-IPF registry Respir Res 18 139-8
[10]  
Martinez FJ(2018)Patients’ perceptions and patient-reported outcomes in progressive-fibrosing interstitial lung diseases Eur Respir Rev 36 779-719
12345678910